LJ-2698 is under clinical development by Future Medicine and currently in Phase I for Glaucoma. According to GlobalData, Phase I drugs for Glaucoma have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LJ-2698’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LJ-2698 overview
LJ-2698 (FM-101) is under development for the treatment of ocular hypertension, diabetic nephropathy, glaucoma, non-alcoholic fatty liver disease, primary biliary cholangitis and non-alcoholic steatohepatitis. The drug candidate is a nucleoside derivative. It is administered through oral route. It acts by targeting A3 adenosine receptor.
See Also:
Future Medicine overview
Future Medicine is a company that develops drugs using a nucleoside library platform. The company is headquartered in Seongnam, Gyeonggi-do, Republic of Korea (South Korea).
For a complete picture of LJ-2698’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.